Start by translating the product number
The advertised sequence is Crystal Retinal 1, 3, 6, 10, 20 and 24. The corresponding retinaldehyde amounts are 0.01%, 0.03%, 0.06%, 0.1%, 0.2% and 0.24%. This mapping matters because the large version number is not itself the ingredient percentage. Source 1
These are retinal products, not prescription tretinoin creams. A numerical comparison across different vitamin A forms cannot establish equal effect or tolerance. Our cream and serum comparison considers why product identity needs more than a package format. Here the exact numbered version is an essential part of that identity and should stay attached to every price or study note.
The eleven-times claim needs its original endpoint
The manufacturer connects eleven-times-faster language to biochemical conversion evidence, including a 1990 study of vitamin A metabolism in keratinocytes. That is a different question from how quickly a visible facial line improves when someone applies the commercial product. We have not treated the laboratory comparison as a clinical stopwatch. Source 1
A reader should not use the multiple to shorten another treatment’s expected course or to predict an individual result. The observation does not establish that Crystal Retinal produces eleven times the wrinkle improvement of tretinoin. Translating an ingredient-pathway finding into a finished-product outcome would require additional evidence that this public-source review has not established.
Keep the 33-person study with Crystal Retinal 6
The product page describes twelve-week findings in 33 people using version 6. Its reported wrinkle, pigmentation, firmness and participant-perception measures have different meanings. A participant saying skin looks more youthful is not the same measurement as an investigator’s assessment of a particular visible feature. Source 1
The short ten-day image presentation should also stay separate from the twelve-week study. We did not verify that every photograph, testimonial and percentage comes from one protocol. Most importantly, the version 6 findings cannot simply be assigned to every lower or higher strength. Our before-and-after guide explains why time, preparation and measurement method must travel together.
The lowest visible price is only a starting point
The reviewed US listing displayed a starting amount of $56. Availability and the selected version still need confirmation. A stock-notification option is not evidence that the desired tube can be dispatched immediately, and we did not complete a basket to establish the final delivered price. Source 1
The brand’s estimated number of uses does not establish a personal monthly expense. Amount per application and frequency affect how long a tube lasts, and neither was observed in this review. The refill-cost guide provides a way to record assumptions explicitly, avoiding a comparison between a verified purchase amount and an invented calendar duration.
Read the return window before opening the tube
Medik8’s US policy starts its thirty-day period at purchase. It requires authorization and at least half the product remaining; kits have additional whole-kit return conditions. A delivery-based interpretation or a promise of an unrestricted thirty-day trial would therefore misstate the terms we read. Source 2
The transaction record should identify the seller, purchase date and version. We did not test the return process, establish postage for a particular case or measure refund speed. If a parcel arrives later than expected, the purchase date still matters to the written window. That observation does not imply a shipping delay occurred in this review.
A fragrance claim and a tolerance claim are different
The page’s no-artificial-fragrance positioning does not erase the vanilla- and tonka-related ingredients and coumarin shown in the published list. Readers with relevant ingredient concerns should inspect the current package and seek appropriate advice. We do not infer universal tolerance from the absence of a particular marketing category. Source 1
AAD guidance helps frame the discussion about which retinoid may suit a person; it does not endorse this commercial range for every routine. Our evidence assessment stops at a clearly described retinal ladder and manufacturer-reported findings with defined limits. It does not supply a personal escalation plan or a recommendation to choose the strongest available number. Source 3
A fair comparison can now be written as a short record: version and declared amount, the study actually relevant to it, the selected purchase price and the policy deadline. If one of those entries is missing, leave it unresolved. Borrowing the best-looking number from another version would create a more impressive but less accurate product description.